CA2897218A1 - Tdf-related compounds and analogs thereof - Google Patents

Tdf-related compounds and analogs thereof Download PDF

Info

Publication number
CA2897218A1
CA2897218A1 CA2897218A CA2897218A CA2897218A1 CA 2897218 A1 CA2897218 A1 CA 2897218A1 CA 2897218 A CA2897218 A CA 2897218A CA 2897218 A CA2897218 A CA 2897218A CA 2897218 A1 CA2897218 A1 CA 2897218A1
Authority
CA
Canada
Prior art keywords
ser
amino acid
thr
compound
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2897218A
Other languages
English (en)
French (fr)
Inventor
William D. Carlson
Peter C. Keck
Michael Sworin
Dattatreymurty Bosukonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Thrasos Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrasos Innovation Inc filed Critical Thrasos Innovation Inc
Publication of CA2897218A1 publication Critical patent/CA2897218A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
CA2897218A 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof Abandoned CA2897218A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US58051104P 2004-06-17 2004-06-17
US60/580,511 2004-06-17
US60862504P 2004-09-10 2004-09-10
US60/608,625 2004-09-10
US61005404P 2004-09-15 2004-09-15
US60/610,054 2004-09-15
US61873504P 2004-10-14 2004-10-14
US60/618,735 2004-10-14
CA2571218A CA2571218C (en) 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2571218A Division CA2571218C (en) 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof

Publications (1)

Publication Number Publication Date
CA2897218A1 true CA2897218A1 (en) 2006-01-26

Family

ID=35785692

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2897218A Abandoned CA2897218A1 (en) 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof
CA2571218A Expired - Fee Related CA2571218C (en) 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2571218A Expired - Fee Related CA2571218C (en) 2004-06-17 2005-06-17 Tdf-related compounds and analogs thereof

Country Status (6)

Country Link
US (4) US8410246B2 (https=)
EP (3) EP2319526A1 (https=)
JP (5) JP4971149B2 (https=)
AU (1) AU2005265098B2 (https=)
CA (2) CA2897218A1 (https=)
WO (1) WO2006009836A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410246B2 (en) 2004-06-17 2013-04-02 Thrasos, Inc. TDF-related compounds and analogs thereof
KR101338533B1 (ko) * 2005-07-19 2013-12-12 스템젠 에스.피.에이. Ｌｉｆ 및 ｂｍｐ에 의한 종양 줄기 세포의 종양발생가능성의 억제
AU2012201060B2 (en) * 2005-09-20 2015-01-22 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
DK2497780T3 (en) * 2005-09-20 2015-06-01 Thrasos Innovation Inc TDF-related compounds and analogs thereof
WO2008150550A1 (en) * 2007-06-05 2008-12-11 Cornell University Compounds for enhancing p21 expression and methods of use thereof
DE102007045919B4 (de) 2007-09-26 2018-07-05 Bayer Intellectual Property Gmbh Wirkstoffkombinationen mit insektiziden und akariziden Eigenschaften
DE102007045957A1 (de) 2007-09-26 2009-04-09 Bayer Cropscience Ag Wirkstoffkombinationen mit insektiziden und akarziden Eigenschaften
DE102007045956A1 (de) 2007-09-26 2009-04-09 Bayer Cropscience Ag Wirkstoffkombination mit insektiziden und akariziden Eigenschaften
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
HK1198333A1 (zh) * 2011-07-19 2015-04-02 Thrasos Innovation, Inc. 抗纤维化肽及其在用於治疗以纤维化为特徵的疾病和病症的方法中的用途
SG10201801654RA (en) 2014-05-28 2018-04-27 Childrens Hospital Med Ct Methods and systems for converting precursor cells into gastric tissues through directed differentiation
WO2016010844A1 (en) * 2014-07-14 2016-01-21 Tarix Pharmaceuticals Ltd Methods and compositions for the treatment of stroke
AU2015331848B2 (en) 2014-10-17 2022-03-03 Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
WO2016077539A1 (en) * 2014-11-12 2016-05-19 Thrasos Innovation, Inc. Peptides with enhanced stability and their use in methods for treating diseases
US11578110B2 (en) 2015-08-25 2023-02-14 Histide Ag Compounds for inducing tissue formation and uses thereof
SG10201913355RA (en) * 2015-09-17 2020-02-27 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
US20190224279A1 (en) * 2015-09-17 2019-07-25 Histide Ag Pharmaceutical association comprising a growth factor receptor agonist conjugated to a bioactive carrier for converting a neoplastic cell into a non-neoplastic cell and uses thereof
US10639352B2 (en) * 2016-04-13 2020-05-05 Chondropeptix B.V. Method for the treatment or prevention of osteoarthritis
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
EP4553082A3 (en) 2016-11-04 2025-08-20 Children's Hospital Medical Center Liver organoid compositions and methods of making and using same
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
JP7248586B2 (ja) 2017-04-14 2023-03-29 チルドレンズ ホスピタル メディカル センター 複数ドナー幹細胞組成物およびそれを作製する方法
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
EP3694603B1 (en) 2017-10-10 2026-04-08 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
EP4678727A3 (en) 2018-07-26 2026-03-11 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
CA3112026A1 (en) 2018-09-12 2020-03-19 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
US11361161B2 (en) * 2018-10-22 2022-06-14 Verint Americas Inc. Automated system and method to prioritize language model and ontology expansion and pruning
US12600943B2 (en) 2019-02-01 2026-04-14 The University Of Hong Kong Innervated organoid compositions and methods of making same
US12492399B2 (en) * 2019-03-14 2025-12-09 Rena Therapeutics Inc. Nucleic acid complex for regulating IHH expression
AU2020283048A1 (en) 2019-05-31 2021-12-23 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
US12497597B2 (en) 2019-05-31 2025-12-16 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
WO2022020711A1 (en) * 2020-07-24 2022-01-27 The Texas A&M University System Sars-cov-2 main protease inhibitors
CA3212468A1 (en) * 2021-03-16 2022-09-22 William D. Carlson Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis
CN116218774A (zh) * 2021-03-26 2023-06-06 广西大学 一种体外高效诱导人体细胞重编程为神经元细胞的方法
WO2024081245A1 (en) * 2022-10-10 2024-04-18 Therapeutics By Design, LLC Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury
CN117045795B (zh) * 2023-08-11 2026-01-09 中南大学湘雅三医院 一种Hedgehog通路抑制剂在防治动脉搭桥术后并发症的制药用途

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4768523A (en) 1981-04-29 1988-09-06 Lifecore Biomedical, Inc. Hydrogel adhesive
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
GB8630273D0 (en) 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US5092871A (en) 1987-03-13 1992-03-03 Brown University Research Foundation Electrically-charged nerve guidance channels
US5041126A (en) 1987-03-13 1991-08-20 Cook Incorporated Endovascular stent and delivery system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5213580A (en) 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4955892A (en) 1988-10-24 1990-09-11 Louisiana State University Neural cell adhesion protein nerve prosthesis
US5089606A (en) 1989-01-24 1992-02-18 Minnesota Mining And Manufacturing Company Water-insoluble polysaccharide hydrogel foam for medical applications
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
JPH085780B2 (ja) 1989-04-28 1996-01-24 呉羽化学工業株式会社 変形性関節症治療剤
JPH04501510A (ja) 1989-07-25 1992-03-19 セル　ジェネシス，インコーポレイティド 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同性組換え
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
US5052998A (en) 1990-04-04 1991-10-01 Zimmon David S Indwelling stent and method of use
US5064435A (en) 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
MA22668A1 (fr) 1990-07-10 1993-07-01 Smithkline Beecham Corp Procede de preparation d'oxamides .
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
DK0575555T3 (da) 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
US5147370A (en) 1991-06-12 1992-09-15 Mcnamara Thomas O Nitinol stent for hollow body conduits
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DE69233559T2 (de) 1991-08-30 2006-08-31 Curis, Inc., Cambridge Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
JP3693338B2 (ja) 1991-08-30 2005-09-07 キュリス インコーポレイテッド 組織形成因子誘導による炎症反応の調節
US5525519A (en) 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
US5176626A (en) 1992-01-15 1993-01-05 Wilson-Cook Medical, Inc. Indwelling stent
US5683448A (en) 1992-02-21 1997-11-04 Boston Scientific Technology, Inc. Intraluminal stent and graft
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
PT653942E (pt) 1992-07-31 2003-11-28 Curis Inc Regeneracao e reparacao de nervos induzidos por morfogenios
EP0680334B1 (en) 1992-09-15 2000-12-13 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
CA2144514C (en) 1992-09-16 2002-03-26 Thangavel Kuberasampath Morphogen-induced liver regeneration
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
CA2149441C (en) 1992-11-17 2004-03-02 Kohei Miyazono Activin receptor-like kinases, proteins having serine threonine kinase domains and their use
US5579591A (en) 1993-06-29 1996-12-03 Limited Responsibility Company Frontier Footwear for patients of osteoarthritis of the knee
EP0741783B1 (en) 1993-12-30 2009-03-18 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
EP0756628B1 (en) 1994-04-29 2007-11-14 Curis, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
US5614609A (en) 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
US6210899B1 (en) 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
US6306622B1 (en) 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5681274A (en) 1995-03-31 1997-10-28 Boston Scientific Corporation Variable length uretheral stent
US5569676A (en) 1995-05-24 1996-10-29 Diehl; Harry W. Method for the treatment of osteoarthritis
CA2229557A1 (en) 1995-08-14 1997-02-27 Creative Biomolecules, Inc. Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
US5989827A (en) 1995-11-14 1999-11-23 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
WO1997026277A2 (en) * 1996-01-22 1997-07-24 Creative Biomolecules, Inc. Morphogen analogs and methods for producing them
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
EP0894004B2 (en) 1996-03-22 2007-02-21 Curis, Inc. Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma
EP0968430A1 (en) 1997-03-07 2000-01-05 Mount Sinai Hospital Corporation Methods to diagnose a required regulation of trophoblast invasion
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
US6111066A (en) 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
US6198281B1 (en) 1997-11-12 2001-03-06 The Research Foundation Of State University Of New York NMR spectroscopy of large proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP3561738B2 (ja) 1998-06-02 2004-09-02 株式会社リガク Ｂｒａｇｇ反射自動選出方法および装置並びに結晶方位自動決定方法およびシステム
JP2002521025A (ja) 1998-07-24 2002-07-16 ザ カーネギー インスチチューション オブ ワシントン 増殖因子のＴＧＦ−βファミリーのメンバーを使用する、生殖系列幹細胞の維持および増殖のための方法。
JP2002524528A (ja) 1998-09-11 2002-08-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法
US6329184B1 (en) 1998-12-18 2001-12-11 Pharmacia & Upjohn Ab Crystalline form of activated tartrate-resistant and purple acid phosphatase
US6444802B1 (en) * 1999-09-30 2002-09-03 Millenium Pharmaceuticals, Inc. Human aminopeptidase
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6468346B2 (en) 1999-12-10 2002-10-22 Bsi Proteomics Corporation Applying x-ray topography and diffractometry to improve protein crystal growth
AU2001239947A1 (en) 2000-02-29 2001-09-12 Curis, Inc. Methods and compositions for regulating adipocytes
US6699278B2 (en) 2000-09-22 2004-03-02 Cordis Corporation Stent with optimal strength and radiopacity characteristics
EP1334442A2 (en) 2000-11-06 2003-08-13 Thrasos, Inc. Computer method and apparatus for classifying objects
WO2002039118A1 (en) 2000-11-06 2002-05-16 Thrasos, Inc. Screening methods for bone morphogenetic mimetics
US20040031066A9 (en) 2001-01-18 2004-02-12 Faustman Denise L. Mouse model for rheumatoid arthritis
US6679911B2 (en) 2001-03-01 2004-01-20 Cordis Corporation Flexible stent
EP1383867A2 (en) 2001-03-23 2004-01-28 Axordia Limited Stem cell differentiation
US6673106B2 (en) 2001-06-14 2004-01-06 Cordis Neurovascular, Inc. Intravascular stent device
US20030103959A1 (en) 2001-06-22 2003-06-05 Hughes Paul E. Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor
WO2003106972A2 (en) * 2002-06-17 2003-12-24 Thrasos, Inc. Multiple domain tdf-related compounds and analogs thereof
WO2003106656A2 (en) * 2002-06-17 2003-12-24 Thrasos, Inc. Single domain tdf-related compounds and analogs thereof
US20040093164A1 (en) 2002-11-08 2004-05-13 Carlson William D. Computer system and methods for producing morphogen analogs of human TDF-1
US8410246B2 (en) 2004-06-17 2013-04-02 Thrasos, Inc. TDF-related compounds and analogs thereof
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
JP2013034477A (ja) 2013-02-21
JP2008512087A (ja) 2008-04-24
JP4971149B2 (ja) 2012-07-11
US20150132355A1 (en) 2015-05-14
JP2015013894A (ja) 2015-01-22
JP2012019788A (ja) 2012-02-02
WO2006009836A3 (en) 2007-08-23
EP1773871A4 (en) 2008-07-16
US8916686B2 (en) 2014-12-23
CA2571218C (en) 2015-11-03
CA2571218A1 (en) 2006-01-26
EP2319526A1 (en) 2011-05-11
US9181301B2 (en) 2015-11-10
US20100015150A1 (en) 2010-01-21
US8410246B2 (en) 2013-04-02
EP2789342A1 (en) 2014-10-15
EP1773871B1 (en) 2014-10-15
JP2016155855A (ja) 2016-09-01
EP1773871A2 (en) 2007-04-18
JP5829193B2 (ja) 2015-12-09
AU2005265098B2 (en) 2012-02-23
JP5513449B2 (ja) 2014-06-04
US20160152674A1 (en) 2016-06-02
WO2006009836A2 (en) 2006-01-26
AU2005265098A1 (en) 2006-01-26
US20140044754A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
US9181301B2 (en) TDF-related compounds and analogs thereof
US8911953B2 (en) TDF-related compounds and analogs thereof, analogs and bioactive fragments
AU2012201060B2 (en) TDF-related compounds and analogs thereof
AU2012200042B2 (en) TDF-related compounds and analogs thereof
AU2015200812A1 (en) TDF-related compounds and analogs thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150713

FZDE Discontinued

Effective date: 20171110